Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cellectis SA ( (FR:ALCLS) ) has shared an update.
Cellectis has reported its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs and strategic partnerships. The company is advancing its UCART22 and UCART20x22 programs, with key data readouts expected in 2025. Cellectis has also strengthened its collaboration with AstraZeneca, which includes an additional equity investment of $140 million, ensuring financial stability until mid-2027. The company’s focus remains on developing next-generation genomic medicines to address unmet patient needs.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that utilizes its pioneering gene editing platform to develop life-saving cell and gene therapies. The company focuses on creating allogeneic CAR T-cell therapies and gene therapies, with a significant partnership with AstraZeneca to advance these innovative treatments.
YTD Price Performance: -16.67%
Average Trading Volume: 950
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $95.46M
See more insights into ALCLS stock on TipRanks’ Stock Analysis page.